RESEARCH PROFILE
NAD+
Nicotinamide Adenine Dinucleotide • Cellular Energy & Metabolic Research
NAD+ is an essential coenzyme found in living cells and involved in cellular energy production, redox reactions, DNA repair, mitochondrial function, and signaling pathways associated with cellular stress and aging.
Although NAD+ is frequently grouped with peptide and longevity research, it is not a peptide. Human research is considerably stronger for oral NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide than for injected NAD+ itself.
ESSENTIAL CELLULAR COENZYME • INJECTABLE NAD+ NOT FDA APPROVED • DIRECT HUMAN EVIDENCE LIMITED
NAD+ AT A GLANCE
Full Name
Nicotinamide adenine dinucleotide
Compound Type
Cellular coenzyme
Is It a Peptide?
No
Primary Research Focus
Cellular energy • Redox biology • DNA repair • Sirtuin signaling • Mitochondrial function
Major Biological Roles
Electron transfer • ATP production • PARP activity • Sirtuin activity • Cellular signaling
Human Evidence
Strongest for oral NAD+ precursors; limited for direct injectable NAD+
Regulatory Status
Injectable NAD+ is not FDA approved as a therapeutic drug
IMPORTANT DISTINCTION
NAD+ is often discussed alongside peptides because injectable NAD+ appears in research, wellness, recovery, and longevity protocols.
Biochemically, however, NAD+ is not a peptide.
It is a naturally occurring coenzyme required for fundamental cellular reactions.
Another important distinction is between:
NAD+ itself
and
NAD+ precursors such as NR and NMN
Evidence that an oral precursor raises blood NAD+ or affects a biomarker should not automatically be attributed to injected NAD+.
WHAT IS NAD+?
NAD+ stands for nicotinamide adenine dinucleotide.
It is present throughout the body and participates in reactions essential to cellular metabolism.
NAD exists primarily in two interconvertible forms:
NAD+
Oxidized form
NADH
Reduced form
This NAD+/NADH system allows electrons to move between biochemical reactions.
That electron transfer is fundamental to the way cells convert nutrients into usable energy.
CELLULAR ENERGY
NAD+ participates in metabolic pathways that process:
Glucose
Fatty acids
Amino acids
The resulting electrons ultimately contribute to mitochondrial ATP production.
MORE THAN ENERGY
NAD+ is also consumed by enzymes involved in:
DNA repair
Gene regulation
Cellular stress response
Inflammatory signaling
Mitochondrial biology
This dual role as both a metabolic coenzyme and signaling substrate is a major reason NAD+ has become a focus of aging and longevity research.
MECHANISM OF ACTION
NAD+ participates in several major cellular systems rather than acting through a single receptor.
ENERGY PRODUCTION
NAD+ accepts and transfers electrons during metabolic reactions.
NADH then carries those electrons into mitochondrial energy pathways.
This process contributes to the electrochemical gradient ultimately used to produce ATP, the primary cellular energy currency.
NAD+ / NADH REDOX SYSTEM
The balance between NAD+ and NADH is central to cellular redox biology.
Rather than functioning as a conventional stimulant, NAD+ participates directly in the chemistry cells use to process energy.
DNA REPAIR & PARP ENZYMES
PARP enzymes use NAD+ during responses to DNA damage.
When DNA damage increases, PARP activity can consume substantial amounts of NAD+.
This creates a mechanistic connection between:
DNA damage
NAD+ availability
Cellular stress
Energy metabolism
SIRTUINS
Sirtuins are a family of NAD+-dependent enzymes involved in cellular regulation.
Research has linked sirtuins with:
Gene expression
Mitochondrial biology
Metabolic regulation
Stress response
Aging-related pathways
NAD+ availability can therefore influence sirtuin activity.
CD38 & NAD+ CONSUMPTION
CD38 is another NAD+-consuming enzyme.
Your Project source describes research suggesting that CD38 activity increases with age and chronic inflammatory signaling, potentially contributing to age-associated NAD+ decline.
AGE-RELATED NAD+ DECLINE
NAD+ levels appear to decline in various tissues with aging.
Researchers are investigating whether restoring NAD+ availability can influence age-related metabolic and cellular changes.
IMPORTANT MECHANISM LIMITATION
A biological role in energy production and aging pathways does not establish that administering exogenous NAD+:
Increases energy in healthy people
Reverses aging
Improves athletic performance
Repairs DNA clinically
Extends lifespan
Mechanistic plausibility and demonstrated clinical benefit are different levels of evidence.
WHAT THE RESEARCH SHOWS
HUMAN NAD+ RESEARCH
NAD+ biology is extensively studied.
However, the Project source makes an important distinction:
Most published human randomized-trial evidence aimed at increasing NAD+ uses oral precursors such as NR and NMN rather than direct injectable NAD+.
NICOTINAMIDE RIBOSIDE — NR
Multiple randomized human studies cited in the Project profile have shown that oral nicotinamide riboside can raise blood NAD+-related metabolites.
Trials have generally reported favorable tolerability across studied doses.
However, increasing a NAD+ biomarker does not automatically mean improved clinical outcomes.
NICOTINAMIDE MONONUCLEOTIDE — NMN
Human research involving NMN is growing.
The Project profile cites randomized research reporting improved muscle insulin sensitivity in a specific population of postmenopausal women with prediabetes.
Other dose-response research has demonstrated increases in NAD+-related biomarkers.
Again, those findings involve NMN, not direct NAD+ injection.
DIRECT INJECTABLE NAD+
Human evidence for direct injectable NAD+ is much more limited.
Your Project source identifies:
Historical IV case reports
Pilot pharmacokinetic research
Small clinical observations
A 2024 systematic review examining NAD+-related interventions
The Project profile does not identify a large randomized clinical evidence base establishing injectable NAD+ for general wellness or longevity.
SUBCUTANEOUS NAD+
This is particularly important for the Croix research profile.
Your Project source states that:
Large-scale, long-duration randomized controlled trials of subcutaneous NAD+ for wellness or longevity endpoints had not been published as of June 2026.
Therefore, community protocols involving subcutaneous NAD+ should not be represented as clinically validated treatment regimens.
AGING RESEARCH
NAD+ decline with age has been documented across multiple experimental systems.
Animal research suggests that restoring NAD+ availability can influence aspects of:
Mitochondrial function
Metabolism
Inflammation
Age-related physiology
Translation into meaningful human longevity outcomes remains uncertain.
ONGOING RESEARCH
The Project source identifies continued clinical investigation of NAD+-related interventions, including studies involving vascular aging and precursor supplementation.
IMPORTANT EVIDENCE LIMITATION
There is currently insufficient evidence in the Project source to conclude that injectable NAD+:
Extends human lifespan
Reverses biological aging
Treats chronic fatigue
Improves cognition in healthy adults
Improves athletic performance
Produces sustained weight loss
Prevents age-related disease
The biological importance of NAD+ is well established.
The clinical benefits of injecting additional NAD+ are much less established.
SAFETY & RESEARCH CONSIDERATIONS
The safety profile of NAD+ depends significantly on route, concentration, amount, and administration rate.
Direct injectable NAD+ has a much smaller controlled human safety literature than its widespread wellness use might suggest.
REPORTED SUBCUTANEOUS EFFECTS
Your Project profile identifies commonly reported effects including:
Injection-site stinging
Burning
Redness
Temporary nodules
Nausea
Headache
Flushing
Temporary fatigue
Occasional sleep disruption
These reports are not equivalent to a large controlled adverse-event database.
IV ADMINISTRATION
The Project source identifies several effects particularly associated with faster intravenous administration:
Flushing
Warmth
Chest tightness
Shortness of breath
Mild headache
Transient vasodilation
The source notes that some of these effects may be rate dependent.
ACTIVE MALIGNANCY
This is an important theoretical consideration.
NAD+ supports fundamental cellular metabolism and proliferation, including in abnormal cells.
Your Project source therefore identifies active malignancy as an area requiring caution and appropriate oncology involvement, rather than portraying NAD+ as either anti-cancer or cancer-promoting.
LIVER & KIDNEY FUNCTION
The Project profile identifies severe hepatic or renal impairment as an area warranting additional caution, particularly with higher-exposure protocols.
GLUCOSE-LOWERING MEDICATIONS
Because NAD+ metabolism intersects with cellular energy and glucose regulation, the Project source recommends caution with concurrent glucose-lowering medications.
LONG-TERM SAFETY
Long-term human safety data for repeated high-dose injectable NAD+ remain limited.
PRODUCT QUALITY
Injectable product quality adds independent concerns involving:
Identity
Concentration
Sterility
Stability
Contamination
Storage conditions
Research-grade or compounded NAD+ should not be assumed equivalent to an FDA-approved drug product.
REGULATORY CONTEXT
INJECTABLE NAD+ IS NOT FDA APPROVED AS A THERAPEUTIC
Your Project profile states that injectable NAD+ is not FDA approved for any therapeutic indication in the United States.
It is available in some compounded preparations and wellness settings, but availability does not constitute FDA approval.
COMPOUNDED NAD+
A compounded preparation is not an FDA-approved drug.
FDA does not review compounded drugs through the same premarket approval process used for approved prescription drug products.
ORAL NAD+ PRECURSORS
The regulatory status of oral precursors differs from injectable NAD+.
Your Project profile specifically notes that nicotinamide riboside, or NR, has GRAS and New Dietary Ingredient-related history in the United States.
That regulatory history applies to NR and should not be generalized to injectable NAD+.
NMN
Your Project source separately identifies NMN as having a more complicated U.S. dietary-supplement regulatory history.
Again:
NAD+ ≠ NR ≠ NMN
Their evidence bases, formulations, and regulatory histories should not be merged.
INTERNATIONAL STATUS
The Project profile notes that regulatory treatment of NAD+-related products differs internationally.
IMPORTANT REGULATORY DISTINCTION
Naturally occurring in the body ≠ FDA-approved therapeutic
Compounded availability ≠ FDA approval
Evidence for NR or NMN ≠ approval of injectable NAD+
Research use ≠ established clinical benefit
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
LOT SPECIFIC ANALYTICAL DOCUMENTATION
Analytical documentation is displayed only when Croix has a corresponding laboratory report that can be matched to the specific product and lot.
No matching NAD+ COA is currently displayed.
IMPORTANT COA LIMITATION
When analytical documentation becomes available, results should apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Yoshino J, Baur JA, Imai SI.
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.
Cell Metabolism. 2018.
Review of NAD+ biology, NAD+ precursors, metabolism, and aging-related research.
Covarrubias AJ, Perrone R, Grozio A, Verdin E.
NAD+ metabolism and its roles in cellular processes during ageing.
Nature Reviews Molecular Cell Biology. 2021.
Comprehensive review of NAD+ metabolism and aging biology.
Martens CR, Denman BA, Mazzo MR, et al.
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.
Nature Communications. 2018.
Human randomized research involving oral NR.
Conze D, Crespo-Barreto J, Kruger CL.
Safety research involving sustained nicotinamide riboside supplementation in healthy adults.
Scientific Reports. 2019.
Human NR safety research.
Dollerup OL, Christensen B, Svart M, et al.
Randomized placebo-controlled human research involving nicotinamide riboside.
Elhassan YS, Kluckova K, Fletcher RS, et al.
Research examining nicotinamide riboside and the aged human skeletal-muscle NAD+ metabolome and transcriptome.
Cell Reports. 2019.
Yoshino M, Yoshino J, Kayser BD, et al.
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
Science. 2021.
Randomized human NMN research.
Yi L, et al.
Dose-response human research examining nicotinamide mononucleotide and NAD+-related biomarkers.
Geroscience. 2023.
Brakedal B, et al.
NADPARK Study research involving nicotinamide riboside in Parkinson's disease.
Cell Metabolism. 2022.
Connell NJ, et al.
Review of NAD+ metabolism and potential therapeutic strategies.
Kim S, et al.
Systematic review examining NAD+-related interventions and aging-related outcomes.
ClinicalTrials.gov
NCT07328100 — Coenzyme I / NAD+-related research involving vascular aging, as cited in the Project profile.
EVIDENCE NOTE
The biological importance of NAD+ is exceptionally well established.
However, the clinical evidence must be separated by intervention.
Oral NR and NMN have substantially more randomized human evidence than direct injectable NAD+.
Findings from precursor studies should not be presented as proof that subcutaneous or intravenous NAD+ produces the same outcomes.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish injectable NAD+ as safe or effective for personal use.
NAD+ is an essential cellular coenzyme, not a peptide. It participates in cellular energy metabolism, redox reactions, DNA-repair pathways, sirtuin signaling, and other fundamental biological processes.
The importance of NAD+ to normal cellular biology is well established. The clinical benefits of administering additional NAD+ by injection are much less certain.
Human randomized evidence is substantially stronger for oral NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide than for direct injectable NAD+.
Injectable NAD+ is not FDA approved as a therapeutic drug, and large long-duration randomized trials establishing subcutaneous NAD+ for longevity or general wellness were not identified in the Project source.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.